ArticleTransboundary and emerging diseases2025
Crimean-Congo Hemorrhagic Fever Virus Infections in Slaughtered Camels and Abattoir Workers in the United Arab Emirates.
Article in Transboundary and emerging diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Pathogenicity and virulence of Crimean-Congo hemorrhagic fever virus: From enzootic maintenance to severe human disease.Virulence · 2026Review
- Integrated surveillance, virus isolation and phylogenetic characterization of Crimean-Congo hemorrhagic fever virus in Central Kazakhstan.Frontiers in veterinary science · 2026Article
- Serosurvey of Crimean-Congo Hemorrhagic Fever Virus in dromedary camels (Frontiers in veterinary science · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Crimean-Congo hemorrhagic fever (CCHF) is a tick-borne disease caused by the CCHF virus (CCHFV) and is characterized by the sudden onset of high fever and hemorrhagic manifestations. This study aimed to estimate the seroprevalence of anti-CCHFV antibodies in dromedary camels and workers at the Al Bawadi abattoir in the United Arab Emirates (UAE). In addition, the camels and human subjects were screened for CCHFV RNA, and the knowledge level of abattoir workers regarding CCHF zoonosis was assessed. A cross-sectional study was conducted between March 2022 and June 2023 at the Al-Bawadi abattoir in Al Ain with 393 camels and 86 abattoir workers. Anti-CCHFV immunoglobulin G (IgG) antibody was tested in camel sera using a multispecies indirect enzyme-linked immunosorbent assay (ELISA). The sera of abattoir workers were tested for anti-CCHFV IgG antibody using a human CCHFV ELISA kit. Camel and human serum samples were tested by reverse transcription quantitative real-time polymerase chain reaction (RT-qPCR) to detect CCHFV RNA. A questionnaire survey was used to evaluate abattoir workers' knowledge of the risk of zoonosis of CCHF. The seroprevalence of anti-CCHFV antibodies in camels slaughtered at the Al-Bawadi Abattoir was 65.1% (95% confidence interval [CI]: 60.4%-70%). However, the RNA prevalence was only 1% (4/393), with cycle threshold (Ct) values ranging from 34.58 to 38.21. The seroprevalence of anti-CCHFV antibodies in abattoir workers was 29.1% (95% CI: 20.3%-40.4%), but none of the abattoir workers tested positive by RT-qPCR. Seropositive abattoir workers had a longer duration of working in the abattoir (median = 10 years; interquartile range [IQR]: 6.0-14.0) than seronegative abattoir workers (median = 7.5 years; IQR: 5.0-14.0) although the difference was not significant (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.